OA10691A - Treatment of the cns effects of hiv with vx-478 alone or in combination with azt or 3tc - Google Patents
Treatment of the cns effects of hiv with vx-478 alone or in combination with azt or 3tc Download PDFInfo
- Publication number
- OA10691A OA10691A OA9800067A OA9800067A OA10691A OA 10691 A OA10691 A OA 10691A OA 9800067 A OA9800067 A OA 9800067A OA 9800067 A OA9800067 A OA 9800067A OA 10691 A OA10691 A OA 10691A
- Authority
- OA
- OAPI
- Prior art keywords
- hiv
- compound
- formula
- cns
- viral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/567,199 US5646180A (en) | 1995-12-05 | 1995-12-05 | Treatment of the CNS effects of HIV |
Publications (1)
Publication Number | Publication Date |
---|---|
OA10691A true OA10691A (en) | 2001-05-04 |
Family
ID=24266147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
OA9800067A OA10691A (en) | 1995-12-05 | 1998-05-29 | Treatment of the cns effects of hiv with vx-478 alone or in combination with azt or 3tc |
Country Status (23)
Country | Link |
---|---|
US (1) | US5646180A (pt) |
EP (1) | EP0866696B1 (pt) |
JP (1) | JP2000501713A (pt) |
KR (1) | KR19990071750A (pt) |
CN (1) | CN1203530A (pt) |
AP (1) | AP864A (pt) |
AT (1) | ATE279922T1 (pt) |
AU (1) | AU722850B2 (pt) |
BR (1) | BR9611861A (pt) |
CA (1) | CA2238471A1 (pt) |
CZ (1) | CZ291994B6 (pt) |
DE (1) | DE69633680T2 (pt) |
ES (1) | ES2231828T3 (pt) |
HU (1) | HUP9903673A3 (pt) |
NO (1) | NO317837B1 (pt) |
NZ (1) | NZ324603A (pt) |
OA (1) | OA10691A (pt) |
PL (1) | PL187747B1 (pt) |
PT (1) | PT866696E (pt) |
RU (1) | RU2203658C2 (pt) |
UA (1) | UA61902C2 (pt) |
WO (1) | WO1997020554A1 (pt) |
ZA (1) | ZA9610139B (pt) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6107499A (en) * | 1988-02-26 | 2000-08-22 | Neuromedica, Inc. | Dopamine analog amide |
US5942253A (en) | 1995-10-12 | 1999-08-24 | Immunex Corporation | Prolonged release of GM-CSF |
US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
US6576636B2 (en) | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
PL330747A1 (en) * | 1996-06-25 | 1999-05-24 | Glaxo Group Ltd | Vx478, zidovudin, ftc and/or 3tc containing combinations for use in treating hiv infections |
PE87398A1 (es) * | 1996-06-25 | 1999-01-15 | Glaxo Group Ltd | Combinaciones antivirales |
ZA9710071B (en) * | 1996-11-21 | 1998-05-25 | Abbott Lab | Pharmaceutical composition. |
US6232333B1 (en) | 1996-11-21 | 2001-05-15 | Abbott Laboratories | Pharmaceutical composition |
JP2001525840A (ja) * | 1997-05-17 | 2001-12-11 | グラクソ、グループ、リミテッド | 炭素環式ヌクレオシド1592u89を含有する抗ウイルス的組合せ |
AU8145198A (en) * | 1997-06-16 | 1999-01-04 | Vertex Pharmaceuticals Incorporated | Methods of increasing the bioavailability of stable crystal polymorphs of a compound |
US6576231B2 (en) * | 1997-09-12 | 2003-06-10 | Schering Ag | Methods for treating HIV-Infected Patients by the Administration of GM-CSF and a protease inhibitor |
US6197764B1 (en) | 1997-11-26 | 2001-03-06 | Protarga, Inc. | Clozapine compositions and uses thereof |
US5955459A (en) * | 1997-11-26 | 1999-09-21 | Neuromedica, Inc. | Fatty acid-antipsychotic compositions and uses thereof |
US6153653A (en) * | 1997-11-26 | 2000-11-28 | Protarga, Inc. | Choline compositions and uses thereof |
US5977174A (en) * | 1997-11-26 | 1999-11-02 | Neuromedica, Inc. | Cholinergic compositions and uses thereof |
US6436989B1 (en) * | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
US6309632B1 (en) * | 1998-04-28 | 2001-10-30 | Immunex Corporation | Methods for treating HIV-infected patients by administering GM-CSF |
US20090197827A1 (en) * | 1998-05-29 | 2009-08-06 | Dunn Ben M | Combination Therapy for Treatment of FIV Infection |
US6875773B1 (en) * | 1998-05-29 | 2005-04-05 | Ben M. Dunn | Combination therapy for treatment of FIV infection |
US7235583B1 (en) * | 1999-03-09 | 2007-06-26 | Luitpold Pharmaceuticals, Inc., | Fatty acid-anticancer conjugates and uses thereof |
US6417189B1 (en) | 1999-11-12 | 2002-07-09 | Gpi Nil Holdings, Inc. | AZA compounds, pharmaceutical compositions and methods of use |
DE60112318T4 (de) * | 2000-10-16 | 2008-11-27 | Conor Medsystems, Inc., Menlo Park | Ausdehnbare medizinische Vorrichtung zur Abgabe eines nützlichen Agens |
WO2002076402A2 (en) | 2001-03-23 | 2002-10-03 | Protarga, Inc. | Fatty amine drug conjugates |
ATE556706T1 (de) * | 2001-03-23 | 2012-05-15 | Luitpold Pharm Inc | Fettalkohol-arzneimittel-konjugate |
AU2003217676B2 (en) | 2002-02-22 | 2009-06-11 | Takeda Pharmaceutical Company Limited | Active agent delivery systems and methods for protecting and administering active agents |
UA88313C2 (ru) | 2004-07-27 | 2009-10-12 | Гилиад Сайенсиз, Инк. | Фосфонатные аналоги соединений ингибиторов вич |
US20080269161A1 (en) * | 2005-01-20 | 2008-10-30 | Seth Perry | Compositions and Methods Relating to Mitochondrial Hyperpolarization in Neurological Disease |
CA2634932A1 (en) * | 2005-12-23 | 2007-07-05 | University Of Rochester | Treatment of neuroaids using inhibitors of glycogen synthase kinase (gsk)-3 |
EP2029528A1 (en) * | 2006-04-19 | 2009-03-04 | Abbott GmbH & Co. KG | Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor |
TWI480268B (zh) | 2008-12-09 | 2015-04-11 | Gilead Sciences Inc | 類鐸受體的調節劑 |
US20110223131A1 (en) | 2010-02-24 | 2011-09-15 | Gilead Sciences, Inc. | Antiviral compounds |
US9789012B2 (en) | 2014-02-28 | 2017-10-17 | Attends Healthcare Products, Inc. | Absorbent article with multi-layer folded absorbent core |
WO2016001907A1 (en) | 2014-07-02 | 2016-01-07 | Prendergast Patrick T | Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents. |
AU2015287773B2 (en) | 2014-07-11 | 2018-03-29 | Gilead Sciences, Inc. | Modulators of toll-like receptors for the treatment of HIV |
CA2997955A1 (en) | 2015-09-15 | 2017-03-23 | Gilead Sciences, Inc. | Modulators of toll-like receptors for the treatment of hiv |
CA3101920A1 (en) | 2018-05-28 | 2019-12-05 | Attends Healthcare Products, Inc. | Dryness layer laminate for absorbent articles |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IS2334B (is) * | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
WO1994013629A1 (en) * | 1992-12-11 | 1994-06-23 | Vertex Pharmaceuticals Incorporated | Mannitol derivatives and their use as inhibitors of aspartyl protease |
-
1995
- 1995-12-05 US US08/567,199 patent/US5646180A/en not_active Expired - Lifetime
-
1996
- 1996-05-12 UA UA98073527A patent/UA61902C2/uk unknown
- 1996-12-03 ZA ZA9610139A patent/ZA9610139B/xx unknown
- 1996-12-05 RU RU98112594/14A patent/RU2203658C2/ru not_active IP Right Cessation
- 1996-12-05 PT PT96942917T patent/PT866696E/pt unknown
- 1996-12-05 BR BR9611861A patent/BR9611861A/pt not_active Application Discontinuation
- 1996-12-05 JP JP9521449A patent/JP2000501713A/ja active Pending
- 1996-12-05 CZ CZ19981708A patent/CZ291994B6/cs not_active IP Right Cessation
- 1996-12-05 CN CN96198816A patent/CN1203530A/zh active Pending
- 1996-12-05 AT AT96942917T patent/ATE279922T1/de not_active IP Right Cessation
- 1996-12-05 ES ES96942917T patent/ES2231828T3/es not_active Expired - Lifetime
- 1996-12-05 KR KR1019980704028A patent/KR19990071750A/ko not_active Application Discontinuation
- 1996-12-05 CA CA002238471A patent/CA2238471A1/en not_active Abandoned
- 1996-12-05 PL PL96327061A patent/PL187747B1/pl not_active IP Right Cessation
- 1996-12-05 NZ NZ324603A patent/NZ324603A/xx unknown
- 1996-12-05 AP APAP/P/1998/001340A patent/AP864A/en active
- 1996-12-05 EP EP96942917A patent/EP0866696B1/en not_active Expired - Lifetime
- 1996-12-05 DE DE69633680T patent/DE69633680T2/de not_active Expired - Fee Related
- 1996-12-05 AU AU11486/97A patent/AU722850B2/en not_active Ceased
- 1996-12-05 WO PCT/US1996/019447 patent/WO1997020554A1/en active IP Right Grant
- 1996-12-05 HU HU9903673A patent/HUP9903673A3/hu unknown
-
1998
- 1998-05-29 OA OA9800067A patent/OA10691A/en unknown
- 1998-06-04 NO NO19982556A patent/NO317837B1/no unknown
Also Published As
Publication number | Publication date |
---|---|
CN1203530A (zh) | 1998-12-30 |
DE69633680D1 (de) | 2004-11-25 |
PL327061A1 (en) | 1998-11-23 |
CZ170898A3 (cs) | 1998-09-16 |
JP2000501713A (ja) | 2000-02-15 |
NO982556D0 (no) | 1998-06-04 |
EP0866696A1 (en) | 1998-09-30 |
AU722850B2 (en) | 2000-08-10 |
RU2203658C2 (ru) | 2003-05-10 |
NZ324603A (en) | 2000-08-25 |
AP9801340A0 (en) | 1998-09-30 |
ZA9610139B (en) | 1997-06-17 |
ATE279922T1 (de) | 2004-11-15 |
NO317837B1 (no) | 2004-12-20 |
BR9611861A (pt) | 1999-05-18 |
AP864A (en) | 2000-08-11 |
NO982556L (no) | 1998-06-04 |
US5646180A (en) | 1997-07-08 |
HUP9903673A3 (en) | 2000-08-28 |
CZ291994B6 (cs) | 2003-07-16 |
KR19990071750A (ko) | 1999-09-27 |
DE69633680T2 (de) | 2006-02-23 |
HUP9903673A2 (hu) | 2000-03-28 |
CA2238471A1 (en) | 1997-06-12 |
WO1997020554A1 (en) | 1997-06-12 |
PT866696E (pt) | 2005-03-31 |
UA61902C2 (en) | 2003-12-15 |
ES2231828T3 (es) | 2005-05-16 |
PL187747B1 (pl) | 2004-09-30 |
AU1148697A (en) | 1997-06-27 |
EP0866696B1 (en) | 2004-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
OA10691A (en) | Treatment of the cns effects of hiv with vx-478 alone or in combination with azt or 3tc | |
AU706732B2 (en) | THF-containing sulfonamide inhibitors of aspartyl protease | |
EP1637528B1 (en) | Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease | |
EP0933372B1 (en) | Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors | |
WO1999033793A2 (en) | Prodrugs of aspartyl protease inhibitors | |
IL202633A (en) | History of sulfonamides and the pharmaceutical preparations that feed them | |
WO1994013629A1 (en) | Mannitol derivatives and their use as inhibitors of aspartyl protease | |
MXPA00006316A (es) | Profarmacos de inhibidores de aspartil proteasa | |
MXPA00006315A (en) | Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors |